Lung Cancer News

The addition of atezolizumab to first-line treatment with bevacizumab and chemotherapy significantly prolonged PFS among individuals with advanced nonsquamous non-small cell lung cancer, according to the agent’s manufacturer.

Women were less likely to use CT scans for lung cancer screening than men, even though they are higher risk than men for the disease, according to a presenter at CHEST 2017.

NEW YORK — Oncologists should know the biomarker status of EGFR, ALK, ROS1, BRAF or PD-L1 before the use of chemotherapy to treat lung cancer patients, according to a presenter at Chemotherapy Foundation Symposium.

Warfarin use was associated with a significantly lower rate of cancer incidence across a broad range of malignancies among adults over the age of 50 years, compared with nonuse, according to new research published in JAMA Internal Medicine.

Nivolumab with or without ipilimumab demonstrated greater efficacy among patients with small cell lung cancer who had a high mutation burden, according to results of an exploratory analysis from CheckMate 032 presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Pembrolizumab appeared safe and effective for patients with pretreated PD-L1-positive small cell lung cancer, according to data from the phase 1b KEYNOTE-028 study published in Journal of Clinical Oncology.

Durvalumab extended PFS without worsening symptoms or quality of life among patients with locally advanced, unresectable stage III lung cancer, according to patient-reported outcomes from the phase 3 PACIFIC trial presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Proposed residual tumor classification criteria from International Association for the Study of Lung Cancer, or IASLC, appeared accurate among patients with non-small cell lung cancer, according to data presented at IASLC World Conference on Lung Cancer.

First-line pembrolizumab induced significantly longer median OS than chemotherapy among patients with metastatic non-small cell lung cancer and high PD-L1 expression, according to long-term follow-up of KEYNOTE-024 presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

PIK3CA mutation defined a distinct phenotype of large cell neuroendocrine carcinoma of the lung characterized by brain metastases, according to study results presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.